View Older Stories View More Recent Stories

Aug 26, 2024 06:45AM Merck Receives European Commission Approval for WINREVAIR™ (sotatercept) in Combination With Other Pulmonary Arterial Hypertension (PAH) Therapies, for the Treatment of PAH in Adult Patients With Fu
Aug 9, 2024 06:46AM Merck (MRK) to Acquire CN201 from Curon Biopharmaceutical
Aug 9, 2024 06:45AM Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
Aug 8, 2024 06:45AM Merck (MRK) Provides Update on Phase 3 KeyVibe-008 Trial of an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab
Aug 8, 2024 06:45AM Merck Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer
Aug 6, 2024 09:00AM Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
Aug 6, 2024 06:45AM Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070
Aug 1, 2024 08:01AM MilliporeSigma Announces Closing of Mirus Bio Acquisition, Bolstering Viral Vector Bioprocessing Offering
Aug 1, 2024 08:00AM IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer
Jul 30, 2024 06:30AM Merck Announces Second-Quarter 2024 Financial Results
Jul 26, 2024 06:50AM Merck (MRK) Receives Positive EU CHMP Opinion for KEYTRUDA Plus Padcev as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma
Jul 26, 2024 06:50AM Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma
Jul 23, 2024 12:52PM Merck Announces Fourth-Quarter 2024 Dividend
Jul 23, 2024 06:45AM Merck (MRK) Reports Topline Results from Phase 2b/3 Trial of Clesrovimab
Jul 23, 2024 06:45AM Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants
Jul 21, 2024 06:00AM 10 policies if Trump wins and stock implications: Jefferies
Jul 16, 2024 06:45AM Merck to Share New Research and Host Community-Focused Symposia at AIDS 2024
Jul 16, 2024 05:10AM Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing
Jul 12, 2024 06:46AM Merck (MRK) Completes Acquisition of EyeBio
Jul 12, 2024 06:45AM Merck Completes Acquisition of EyeBio
Jul 9, 2024 08:30AM Merck Animal Health Completes Acquisition of Elanco’s Aqua Business
Jul 1, 2024 08:15AM Merck (MRK) and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat
Jul 1, 2024 08:15AM Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Pr
Jul 1, 2024 06:45AM Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30
Jun 28, 2024 06:53AM Merck Receives Positive EU CHMP Opinion for WINREVAIR™ (sotatercept) in Pulmonary Arterial Hypertension (PAH)
Jun 27, 2024 08:18PM CDC’S ACIP Unanimously Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults
Jun 26, 2024 07:45PM Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer
Jun 25, 2024 04:05PM USDA Approves Merck Animal Health’s NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza
Jun 20, 2024 10:00AM Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
Jun 18, 2024 08:00AM MilliporeSigma and The Michael J. Fox Foundation Offer Service to Advance Parkinson’s Research
Jun 17, 2024 05:29PM U.S. FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
Jun 17, 2024 05:15PM Merck (MRK) Announces FDA Approval of KEYTRUDA Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma
Jun 17, 2024 05:15PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma
Jun 5, 2024 06:45AM Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Jun 4, 2024 08:00AM MilliporeSigma Announces Siren Biotechnology as Winner of its North American Advance Biotech Grant
May 29, 2024 07:17AM Merck (MRK): FDA Grants Priority Review to Application for KEYTRUDA Plus Chemo as First-Line Treatment of Patients With Malignant Mesothelioma
May 29, 2024 07:15AM FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Meso
May 29, 2024 07:02AM Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio for a potential value of $3 billion
May 29, 2024 06:45AM Merck (MRK) to Acquire EyeBio for Up to $3B
May 29, 2024 06:45AM Merck to Acquire EyeBio
May 28, 2024 03:12PM Merck Announces Third-Quarter 2024 Dividend
May 28, 2024 10:04AM MilliporeSigma Launches First Software for Complete Data Traceability in Microbial Quality Control
May 28, 2024 06:46AM Merck (MRK) Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint
May 28, 2024 06:45AM Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)
May 22, 2024 01:35PM MilliporeSigma Signs Definitive Agreement to Acquire Mirus Bio, Furthering Ambition to Be a Leading Supplier for Viral Vector Manufacturing
May 15, 2024 06:45AM Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
May 13, 2024 06:47AM Merck (MRK) Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab
May 13, 2024 06:45AM Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
May 9, 2024 06:46AM Merck (MRK) Provides Update on Phase 3 KEYNOTE-B21 Trial of KEYTRUDA Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With
May 9, 2024 06:45AM Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cance
View More Recent Stories View Older Stories